---
title: "Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290949104.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-06-26T09:27:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290949104.md)
  - [en](https://longbridge.com/en/news/290949104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290949104.md)
generator: "portal-rs"
---

# Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Can Absci’s (ABSI) Low-Frequency Hair Loss Therapy Redefine Its Long-Term Platform Potential?](https://longbridge.com/en/news/297731951.md)
- [Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings](https://longbridge.com/en/news/295686913.md)
- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)
- [IAB raises 2026 US ad growth forecast to 12.3 percent](https://longbridge.com/en/news/298865474.md)
- [MANE: Extended-release oral minoxidil shows promise for FDA approval in both male and female hair loss](https://longbridge.com/en/news/298498192.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**